Adial Pharmaceuticals, Inc.
ADIL
$0.00
Change (1 day)
$4.17
Year High
$0.77
Year Low
Categories
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc. (ADIL) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -2,827,082 | 653.08 K | 4.74 M | 3.2 M | |
| 2022 | -3,794,419 | 2.46 M | 5.73 M | 4.78 M | |
| 2021 | -5,805,213 | 3.97 M | 7.47 M | 6.46 M | |
| 2020 | -4,401,114 | 1.51 M | 5.49 M | 5.14 M | |
| 2019 | -6,777,052 | 539.05 K | 7.68 M | 7.67 M |